Diacerein
From Wikipedia, the free encyclopedia
Diacerein
|
|
Systematic (IUPAC) name | |
4,5-diacetyloxy-9,10-dioxo-anthracene-2- carboxylic acid |
|
Identifiers | |
CAS number | |
ATC code | M01 |
PubChem | |
Chemical data | |
Formula | C19H12O8 |
Mol. mass | 368.294 g/mol |
Synonyms | Diacetylrhein, diacerhein |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | 99% |
Metabolism | Hepatic: deacetylation to rhein, later glucuronidation and sulfate conjugation |
Half life | 4 to 5 hours |
Excretion | Renal (30%) |
Therapeutic considerations | |
Pregnancy cat. |
Lacking information |
Legal status | |
Routes | Oral |
Diacerein (INN), also known as diacetylrhein, is a drug used in the treatment of osteoarthritis. It works by inhibiting interleukin-1.
A 2005 Cochrane review found diacerein to be slightly, but significantly, more effective than placebo in controlling the pain of osteoarthritis.[1]
[edit] Side effects
The most common side effects of diacerein treatment are gastrointestinal, such as diarrhea.[1][2]
[edit] References
- ^ a b Fidelix TS, Soares BG, Trevisani VF (2006). "Diacerein for osteoarthritis". Cochrane database of systematic reviews (Online) (1): CD005117. doi: . PMID 16437519. Free summary
- ^ (French) Diacereine. BIAM (March 24, 1999). Retrieved on 2007-06-13.